Celgene vet Barer lines up a $23M startup round for next-gen I/O tech out of Johns Hopkins
After spending the past year in the hot seat as chairman at a badly dysfunctional Teva, Celgene co-funder Sol Barer can get back to the business of ramping up biotech startups. This morning we received word that Barer has lined up a $23 million A round to get I/O fledgling NexImmune into the clinic.
Barer, Joshua Barer and former Medtronic CEO William Hawkins got together early last year — around the time Teva began to come apart at the seams — to acquire the Johns Hopkins spinout, based in Gaithersburg, MD.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.